about
Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapyTrial Watch: Immunomodulatory monoclonal antibodies for oncological indicationsTrial Watch: Immunogenic cell death inducers for anticancer chemotherapyTrial Watch:: Oncolytic viruses for cancer therapyTrial Watch-Immunostimulation with cytokines in cancer therapyTrial Watch: Proteasomal inhibitors for anticancer therapyNovel insights into the mechanism of action of lenalidomide.Novel immune checkpoint blocker approved for the treatment of advanced melanomaNovel and emerging targeted-based cancer therapy agents and methods.Trial watch: Naked and vectored DNA-based anticancer vaccinesThe IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myelomaCutaneous and systemic plasmacytosis on the face: Effective treatment of a case using thalidomide.FN14 and GRP94 expression are prognostic/predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies.T cells in multiple myeloma display features of exhaustion and senescence at the tumor site.Mobilization with cyclophosphamide reduces the number of lymphocyte subpopulations in the leukapheresis product and delays their reconstitution after autologous hematopoietic stem cell transplantation in patients with multiple myeloma.Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapyMyeloid-derived suppressor cells: their role in the pathophysiology of hematologic malignancies and potential as therapeutic targets.Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?Natural Killer Cell Immunotherapy: From Bench to BedsideActivation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progressionTherapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease.Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.Trial Watch: Adoptive cell transfer for anticancer immunotherapy.MUC1-C is a target in lenalidomide resistant multiple myeloma.Lenalidomide overcomes the immunosuppression of regulatory CD8+CD28- T-cells.Trial Watch: Chemotherapy with immunogenic cell death inducers.Inhibition of HIF1α-Dependent Upregulation of Phospho-l-Plastin Resensitizes Multiple Myeloma Cells to Frontline Therapy.
P2860
Q26993238-F8C67720-2E6D-4491-9657-0667A47BE8DDQ26996518-8B9B3BC5-A8F8-42F7-BFD2-468F95C23558Q27004011-EDA1179C-F914-4C44-83FD-A97A75DDCC28Q27021951-1FC9D1E9-B3FA-4D6D-AEBD-8CC2B727D24BQ28078725-FCF8C6D9-DB5B-4CD6-9662-038457709BBDQ28082910-CBE7E8AE-F3AC-4FC7-BCE0-20258F75207EQ34373253-47B3D002-49B4-43EC-8CF7-12E0C531A743Q34936394-686B2596-C04D-4A58-B489-172BADFE92BBQ35558057-6C7359A4-2BD4-4B38-9CF0-06C35ABC2BC8Q35798986-1EF21C71-124A-4421-AF12-ECA183BE69A2Q36414249-416DCB92-0343-4947-8862-AD24A5393C3EQ36640773-3FFCC0B4-49D4-4A43-8E4E-5FC121834052Q36688951-FFB522F6-D6D1-4066-A1CC-D8331B68204BQ37390723-4ACED1D4-8B4B-4AE8-ACDA-274CB016CB8EQ37432037-944CD157-5996-41DF-8FB7-3B20FF1BEFB4Q37652790-391066F3-8718-4658-B4AE-C1EC174C7425Q38269370-2BCD7F9F-2875-4FAA-B75C-D9BF0CE43BF1Q38447992-5AAA7924-04B3-4581-9C80-755CFB95E08EQ38531958-0D607C18-BFD3-4DBF-9BDA-52DBC86D272BQ39136762-7AEE3BF5-5BBB-4B02-9AF0-D1C28296F9BFQ42318570-B01D3A4C-1A37-467E-B8CD-7D5BFFA11B06Q42558833-B8D3D17E-549F-4E08-9360-60A42E63661DQ42702234-7B7DB6D4-B260-4EBD-8448-D1AEB5FDC125Q46345708-E76F48F5-02EB-4466-8817-15210118E18BQ47112048-BC324BF3-7E83-40C7-979E-0129C186EDB0Q55260834-A7D6C3B8-4913-4C56-99F7-60CAE1AA116DQ55642634-836D7E3F-5D42-4531-9A50-152A62AFC1F2
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Trial Watch: Lenalidomide-based immunochemotherapy.
@en
Trial Watch: Lenalidomide-based immunochemotherapy.
@nl
type
label
Trial Watch: Lenalidomide-based immunochemotherapy.
@en
Trial Watch: Lenalidomide-based immunochemotherapy.
@nl
prefLabel
Trial Watch: Lenalidomide-based immunochemotherapy.
@en
Trial Watch: Lenalidomide-based immunochemotherapy.
@nl
P2860
P50
P356
P1433
P1476
Trial Watch: Lenalidomide-based immunochemotherapy.
@en
P2093
Alexander Eggermont
Michaela Semeraro
P2860
P304
P356
10.4161/ONCI.26494
P50
P577
2013-10-21T00:00:00Z